Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Total market size is incorrect. Vyvanse alone just came off patent with $5B market. It will shrink fast with generic competition and maybe be half that within a year. Regardless, we are still in the billions. We have 10%+ of Adderall IR market, but doubt we will capture that much of rest of CNS space.
If we are first to file/launch for generic oxy, we will initially capture much more than 10% of the market temporarily. It was Interesting to hear Nasrat’s comments on opioids and the issues during last cc and yet an opioid is our next big filing we are waiting on from FDA. Is he having second thoughts? Perhaps they will sell it after approval similar to other opioids we used to own.
When you hit buy/sell in Schwab it shows more decimals. My guess is that is the reason that an order isn’t executing is that the rounding causes confusion and that your bid/ask isn’t being hit.
The one that hostile takeover of that was ever of interest to another company looking to buy elite, which probably wasn’t realistic. Was put in place years ago during SequestOx days.
Jammy stopped posting and you start? Hmmm…
Did jammy sell!?
It’s on the back burner. Not going to be coming off anytime soon. Far too many other promising products for R&D. This would be too much risk, too high of cost and too little market.
Very nice earnings call. Love the forward looking insights. Vyvanse has already been submitted awaiting acceptance response next month. Expecting 4 approvals next year. Solid efficient supply chain strategy with focus on fewer FDA submissions, but all larger products. Laser focused.
Carter did say we still had term loan…eye roll. Boomerang Carter lol
Can’t make call live. Post any notable updates.
Doubtful at best. I think you only heard that from your own rumor. Regardless, awesome quarter. Blew my top line expectations away.
I’m laughing too. Your guess was lower. :)
Carter doesn’t earn $250K per quarter.
Unless someone is pissing our dollars, I’m not expecting it. Can’t imagine the paper cuts that would cause.
I was expecting more of a “golden shower pending” comment that you seem to recycle on other boards. That would have at least brought some warm thoughts…
Nothing under subsequent events, which is where I was expecting a note.
A/R balance skyrocketed over PY qtr. Burning few million in cash until we’re
further down cash conversion cycle. Things are just getting cooking. Awesome quarter.
I’ll happily eat my shorts.
Saw that too. Waiting for Q. Any amount up front would be spread over the duration of agreement. This is the accounting CFO screwed up years ago. Don’t think that’s it. Warrants impact maybe?
I’ll join in the fun. Put me down for an aggressive 10,750,000. This would be a huge stretch. Let’s go Kirko…
Always after the bell.
Why would you expect a drop in profitability? We add CEO pay to cash pmt vs stock + CFO pay that should replace 2 contractors, assuming no longer needing their services. I’d expect nominal increase in spend, but nothing significant.
Company has never had this much going for it. Many fumbles along the way, but finally getting cooking. ELTP has high likelihood of a happy ending.
I recall that one. Thx for posing it. My quote from Nasrat was also mentioned in Q4 cc verbatim.
Great to see the CNS expansion, I’d like to see a shift away from here as well. They have done and will only continue to do better with the CNS market. I just worry about the inherent risk of CNS drugs in general.
I don’t recall this comment from the cc. Curious what Nasrat is thinking. Diversification has been and is still a concern so I’m glad it’s on his mind as the company expands. Adderall ER with Burel, Dexcel and generic Vyvanse are all in the same CNS category. Looking forward to watching this unfold:
“Our goal is to commercialize a new competitive product as we grow and diversify our portfolio.”
Probably because he is in cybersecurity. He is paranoid about everything. Don’t blame him though as I’ve seen plenty of fraudsters try to hack into treasury accounts through a variety of ways to access cash.
I think his angle was from a tax standpoint. I’m referring more from fiscal year standpoint. Tax set of books are separate from financial reporting for variety of reasons. Tax law is not my specialty, but it’s a separate set of books anyway, but does need to be managed in conjunction with shift to new fiscal year.
You can keep replying to me when I have had you on mute for months like an 8 year old petulant child. Please go back to your government cube. You really have no idea what you are talking about.
I think they will do this at year end. I’d be surprised if they did it this quarter. Perhaps.
Awesome to see release and call will be on time.
It is Friday…
I guessing CEO went down this route not knowing the challenge it would be. It will take a good amount of workload beyond just a couple people. Also, the 53rd week wording doesn’t apply to Elite since they are on a calendar year. This occurs with companies that have a fiscal calendar so they can compare each fiscal week to the prior year, but due to leap year you get a 53rd week formed every 6 years, which throws off the comparisons. Never fun. Calendar year fiscal calendar works just perfect for this size company.
Well, we do have trusty old CFO back.
Elite doesn’t have a $5B CNS stimulant filed yet. Let’s get that step done first prior to assuming it’s in the bag.
Nasrat was aware of Burel deal at time of his statements. Will be interesting to see how Burel fares moving from auth generic to regular generic. I’d like to be pleasantly surprised.
One good geographic bonus is that in NJ there is a huge pharma presence. I’m optimistic that additional space won’t be too difficult to find.
Not near future with Burel, but Vyvanse + Oxy might tip the scale in couple years. We have plenty of opportunity for shift expansion that we aren’t even close to maximum utilization.
Vyvanse, oh Vyvanse filing. Where art thou?
Past quarter soon to be reported…
When you are done be sure to pass it around.
Wouldn’t say useless, but it is inconsistent since on OTC, but some data points can be helpful to make decisions.
Nasrat will sell the company. That is the only likely option to liquidate 30% ownership. He has mentioned in the past the company will be for sale at the right price. It’s just timing at the end of the day, but when he wants to sell anyone’s guess. He has been saying NASDAQ is a priority for many years, but now we are actually close to it as we pull a few levers.